Cerner Corporation (CERN)
(Delayed Data from NSDQ)
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Retain NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investor confidence in the stock is high on NuVasive's (NUVA) sturdy spine business.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investor confidence in the stock is high on Hill-Rom's (HRC) recent acquisition of Voalte.
Here's Why You Should Hold Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) raises revenue guidance for 2019 encourages.
Cerner (CERN) Up 9.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Cerner
by Zacks Equity Research
Cerner is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cerner (CERN) Earnings and Revenues Meet Estimates in Q1
by Zacks Equity Research
Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.
CERN vs. TRHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
CERN vs. TRHC: Which Stock Is the Better Value Option?
Zacks.com featured expert Kevin Matras highlights: Ralph Lauren, Cerner, KeyW, Fifth Third and Energy Transfer
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Ralph Lauren, Cerner, KeyW, Fifth Third and Energy Transfer
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Cerner (CERN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Bet on These 5 Stocks With Upgraded Broker Ratings Right Now
by Swayta Shah
Brokers have a deeper understanding of stocks, industries and the overall economy. Thus, it is wise to follow their advice to ensure robust returns.
Cerner (CERN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Cerner (CERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?
by Zacks Equity Research
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.
Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Medidata (MDSO) Surges: Stock Moves 7.5% Higher
by Zacks Equity Research
Medidata (MDSO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Cerner and naviHealth Extend Partnership, Boost EHR Service
by Zacks Equity Research
Cerner (CERN) and naviHealth coordinate to provide EHR offering that is expected to benefit health care providers in the form of affordable and accessible health care centered on the patient.
Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?
by Zacks Equity Research
At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.
Top Ranked Momentum Stocks to Buy for April 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 15th
CERN or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CERN vs. TRHC: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Recently, Cerner (CERN) expanded its reach in the Alabama rural health care market through a new collaboration.
Computer Systems & Jasper General Tie Up to Boost EHR Service
by Zacks Equity Research
Computer Systems (CPSI) sees a series of developments in the EHR platform.
Cerner (CERN) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Stock Reports for Facebook, Johnson & Johnson & JPMorgan
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and JPMorgan (JPM).